China Shineway Pharmaceutical Group Limited faced a challenging first half of 2025, reflecting the broader difficulties within the traditional Chinese medicine (TCM) industry. Crucial pressures, such as reduced market demand, falling procurement prices in centralized purchasing, and stricter cost controls under new medical insurance policies, resulted in a significant downturn in business performance. Shineway’s strategic focus remained on cost control and efficiency, slightly mitigating the impact of the downturn.
Financial Performance and Strategies
During the six-month period ending June 30, 2025, Shineway recorded a 20.8% decline in turnover to RMB1,652,698,000, while gross profit margin decreased from 75.3% last year to 72.2%. Profit fell by 1.9% to RMB614,663,000. Despite these setbacks, the company managed to stabilize earnings per share, which only declined by 2.4% compared to the previous year’s same period. The group enhanced investment income and cut selling, distribution, and administrative expenses by 20.7% and 12.9%, respectively.
Challenges and Market Dynamics
The industry reportedly faced significant shifts due to macroeconomic trends such as diminished consumer confidence and economic slowdown, negatively affecting healthcare consumption. Hospital and retail pharmacy channels also reduced procurement activities amidst the dual-control policies. TCM formula granules faced production cost hikes, while delays in accounts receivable forced shineway to temporarily halt shipments to institutions with overdue debts. Strategic efforts aimed at expanding oral products, accounting for 65.8% of total sales, continued.
Key inferences from Shineway’s management actions include:
- A continued emphasis on cost control and efficiency improvements across operational metrics.
- A tactic to diversify and stabilize income through increased investment and financial products.
- A strategic redirection focusing on strengthening segments with sustained or increased demand, such as exclusive products.
- Enhanced risk assessment protocols in managing accounts receivable and procurement processes.
Sales of injection products plummeted by 27.4%, with critical drops noted in Qing Kai Ling Injection and Shen Mai Injection sales. Concurrently, soft capsule and granule products’ sales decreased by 24.7% and 21.0%, respectively, primarily due to limitations in reaching new market segments outside of established territories. Shineway’s proactive research and development investment, amounting to 3.0% of sales revenue, targeted innovative TCM solutions to expand competitive advantage in chronic and complex diseases.
Despite the industry headwinds, Shineway is poised to leverage its expertise in modernizing TCM. The company has demonstrated resilience through strategic adaptations and focusing on core competencies, which might pave the way for improved subsequent performances. Understanding the macroeconomic climate and adjusting operational gears accordingly remain vital for stakeholders within this evolving pharmaceutical landscape. Enterprises in the TCM sector could benefit from adopting adaptable and innovative business practices, emphasizing agility and strategic foresight to capitalize on market resurgence and policy-driven growth opportunities.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
